This study tests a new weekly injection called CT-388 in 360 adults who are overweight or obese and have type 2 diabetes. The goal is to see if it helps with weight loss and lowers blood sugar over 48 weeks. Participants will receive either the study drug or a placebo, and neithe…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC